Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Omvik

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Managed Care Interface|April 17, 2001
A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertensionJ Doyle, P Omvik, S Arikian, et al.
Journal of Hypertension|December 1, 1990
Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertensionP Lund-Johansen, P Omvik, W White, et al.
Transactions - American Society for Artificial Internal Organs|January 1, 1978
Hemodynamic studies in chronic hemodialysis patients with hemofiltration/ultrafiltrationW T Chen, M Chaignon, P Omvik, et al.
Cardiology|January 1, 1992
Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertensionP Lund-Johansen, P Omvik, W White, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|March 24, 2009
Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE studyE Gerdts, P M Okin, P Omvik, et al.
Kidney International|June 2, 1998
Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure StudyB Timmermann, R Mo, F C Luft, et al.
American Journal of Hypertension|August 19, 2000
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For EndpointS E Kjeldsen, B Dahlöf, R B Devereux, et al.
American Journal of Hypertension|July 1, 1997
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study GroupB Dahlöf, R Devereux, U de Faire, et al.
Hypertension (Dallas, Tex. : 1979)|December 18, 1998
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in HypertensionB Dahlöf, R B Devereux, S Julius, et al.
Journal of the American Society of Nephrology : JASN|March 30, 2023
Lowering Albuminuria-Does It Lower the Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005H Ibsen, M H Olsen, K Wachtell, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Managed Care Interface|April 17, 2001
A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertensionJ Doyle, P Omvik, S Arikian, et al.
Journal of Hypertension|December 1, 1990
Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertensionP Lund-Johansen, P Omvik, W White, et al.
Transactions - American Society for Artificial Internal Organs|January 1, 1978
Hemodynamic studies in chronic hemodialysis patients with hemofiltration/ultrafiltrationW T Chen, M Chaignon, P Omvik, et al.
Cardiology|January 1, 1992
Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertensionP Lund-Johansen, P Omvik, W White, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|March 24, 2009
Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE studyE Gerdts, P M Okin, P Omvik, et al.
Kidney International|June 2, 1998
Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure StudyB Timmermann, R Mo, F C Luft, et al.
American Journal of Hypertension|August 19, 2000
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For EndpointS E Kjeldsen, B Dahlöf, R B Devereux, et al.
American Journal of Hypertension|July 1, 1997
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study GroupB Dahlöf, R Devereux, U de Faire, et al.
Hypertension (Dallas, Tex. : 1979)|December 18, 1998
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in HypertensionB Dahlöf, R B Devereux, S Julius, et al.
Journal of the American Society of Nephrology : JASN|March 30, 2023
Lowering Albuminuria-Does It Lower the Cardiovascular Risk?: Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 45: 198-202, 2005H Ibsen, M H Olsen, K Wachtell, et al.
Pageof 12